Richard Paulson - Feb 28, 2023 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
President and CEO, Director
Signature
/s/Nancy Smith as Attorney-in-Fact for Richard Paulson
Stock symbol
KPTI
Transactions as of
Feb 28, 2023
Transactions value $
-$100,064
Form type
4
Date filed
3/2/2023, 04:28 PM
Previous filing
Feb 8, 2023
Next filing
Mar 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +252K +41.68% $0.00 857K Feb 28, 2023 Direct F1
transaction KPTI Common Stock Sale -$100K -33K -3.86% $3.03 824K Mar 1, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.
F2 This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.